Make or break for Portugal in 2002?
This article was originally published in Clinica
Executive Summary
"2002 is going to be a very strange year" - and a strained one too for the Portuguese medical technology industry, from what Humberto Costa, chairman of leading association Apormed, tells Clinica. Indeed, the problems it faces go beyond issues such as funding, which has already led to apparently insurmountable arrears. For Apormed, the problems afflicting the country's device industry are deeply embedded in systemic, cultural failings of the entire healthcare system, which is in need of reform. As the country prepares for a national election, in which healthcare is set to top the agenda, Mr Costa hints at what he would like to see in the leading parties' manifestos.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.